CL2013000237A1 - Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo. - Google Patents

Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.

Info

Publication number
CL2013000237A1
CL2013000237A1 CL2013000237A CL2013000237A CL2013000237A1 CL 2013000237 A1 CL2013000237 A1 CL 2013000237A1 CL 2013000237 A CL2013000237 A CL 2013000237A CL 2013000237 A CL2013000237 A CL 2013000237A CL 2013000237 A1 CL2013000237 A1 CL 2013000237A1
Authority
CL
Chile
Prior art keywords
vegfa
vivo
decrease
pharmaceutical composition
expression
Prior art date
Application number
CL2013000237A
Other languages
English (en)
Inventor
Anja Smith
Angela Reynolds
Jon E Chatterton
Xinyu Zhang
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45527345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000237(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of CL2013000237A1 publication Critical patent/CL2013000237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
CL2013000237A 2010-07-28 2013-01-24 Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo. CL2013000237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36838510P 2010-07-28 2010-07-28

Publications (1)

Publication Number Publication Date
CL2013000237A1 true CL2013000237A1 (es) 2014-03-21

Family

ID=45527345

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000237A CL2013000237A1 (es) 2010-07-28 2013-01-24 Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.

Country Status (17)

Country Link
US (2) US8546349B2 (es)
EP (1) EP2598639A4 (es)
JP (1) JP2013539456A (es)
KR (1) KR20130095737A (es)
CN (1) CN103068981A (es)
AR (1) AR082411A1 (es)
AU (1) AU2011282902B2 (es)
BR (1) BR112013001918A2 (es)
CA (1) CA2804847A1 (es)
CL (1) CL2013000237A1 (es)
MX (1) MX2013000986A (es)
PH (1) PH12013500187A1 (es)
RU (1) RU2013102545A (es)
TW (1) TW201219041A (es)
UY (1) UY33533A (es)
WO (1) WO2012015775A2 (es)
ZA (1) ZA201300531B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103280A (ko) * 2013-01-08 2015-09-09 베니텍 바이오파마 리미티드 연령-관련 황반 변성 치료
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI496595B (zh) * 2013-06-07 2015-08-21 Univ Nat Taiwan Ocean 製備魚類核醣核酸試劑之方法
KR102298599B1 (ko) * 2014-04-29 2021-09-03 마이크로소프트 테크놀로지 라이센싱, 엘엘씨 샘플 적응 오프셋 필터링에 대한 인코더측 결정
JP2018515142A (ja) * 2015-05-15 2018-06-14 ダーマコン，インコーポレイテッド． Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
GB201802404D0 (en) * 2018-02-14 2018-03-28 Univ Malta Methods
WO2019195936A1 (en) * 2018-04-10 2019-10-17 Ilkow Carolina Solange Microrna-based compositions and methods used in disease treatment
JP7698252B2 (ja) * 2019-09-06 2025-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療薬の核酸媒介性送達
IL295445A (en) * 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
AU2024353921A1 (en) * 2023-09-27 2026-04-16 Neuro3 Therapeutics (Suzhou) Ltd. Novel sirna constructs, therapeutics, and modifications

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306829B1 (en) 1995-12-08 2001-10-23 Hybridon, Inc. Modified VEGF oligonucleotides for treatment of skin disorders
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6150092A (en) 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
WO2002096927A2 (en) 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
JP2000501941A (ja) 1995-12-08 2000-02-22 ハイブリドン・インコーポレイテッド 修飾ｖｅｇｆアンチセンスオリゴヌクレオチド
CA2251945A1 (en) 1996-04-17 1997-10-23 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
WO1998027425A1 (en) 1996-12-19 1998-06-25 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999063975A2 (en) 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system
JP2002529421A (ja) 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
EP1325121A2 (en) 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20100113307A1 (en) 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
JP2008167739A (ja) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
WO2009045356A2 (en) * 2007-09-28 2009-04-09 Yale University Microrna compositions in the treatment of vegf-mediated disorders
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR101397407B1 (ko) * 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
AU2009322279A1 (en) * 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms

Also Published As

Publication number Publication date
WO2012015775A3 (en) 2012-08-09
AR082411A1 (es) 2012-12-05
ZA201300531B (en) 2014-03-26
RU2013102545A (ru) 2014-09-10
AU2011282902B2 (en) 2015-01-29
WO2012015775A2 (en) 2012-02-02
US9150862B2 (en) 2015-10-06
US8546349B2 (en) 2013-10-01
MX2013000986A (es) 2013-07-03
AU2011282902A1 (en) 2013-01-31
KR20130095737A (ko) 2013-08-28
PH12013500187A1 (en) 2013-04-08
JP2013539456A (ja) 2013-10-24
UY33533A (es) 2012-02-29
US20140031414A1 (en) 2014-01-30
EP2598639A2 (en) 2013-06-05
TW201219041A (en) 2012-05-16
EP2598639A4 (en) 2014-08-13
CA2804847A1 (en) 2012-02-02
CN103068981A (zh) 2013-04-24
BR112013001918A2 (pt) 2016-05-24
US20120029051A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
CL2013000237A1 (es) Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
EP3460064B8 (en) Efficient protein expression in vivo using modified rna (mod-rna)
SI3590949T1 (sl) Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
BR112012025375A2 (pt) compósito absorvente, artigo de cuidade pessoal absorvente e método para preparação de um artigo de cuidado pessoal absorvente
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
CL2013001883A1 (es) Metodo de inmunoensayo para vitamina d; inmunoensayo para detectar vitamina 25-oh d en sangre.
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
BR112013033803A2 (pt) formulação integrada com microagulha, e, método para administrar uma substância
EP2563338A4 (en) HIGH SHEAR APPLICATION USED FOR DRUG DELIVERY
BR112014015042A8 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
BR112013014644A2 (pt) composição farmacêutica e complexo
CO7010841A2 (es) Proceso para la preparación de un catalizador que puede ser utilizado en hidrotratamiento e hidroconversión
DK2585112T3 (da) Kollagen-bindende syntetiske peptidoglycaner til anvendelse i vaskulær intervention
BR112013022556A2 (pt) composição farmacêutica aquosa semissólida contendo tapentadol
BR112013010074A2 (pt) composição celulósica e produto
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
CL2013000831A1 (es) Metodo para la determinacion del contenido de alergenos de una composicion.
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
HUE037274T2 (hu) In vivo tumorellenes aktivitással rendelkezõ, humán DLK-1 elleni antitest
CR20130294A (es) Método in vitro para determinar la presencia de piretroides tipo ii